Sharma Lab Deploys Open-LIFU for Multidisciplinary Neurological Research at NC State, UNC

Why It Matters

Demonstrating clinical‑grade neuromodulation with a low‑cost, open‑source ultrasound system could reshape treatment pathways for neurological disorders, reducing reliance on invasive surgery and expensive drug regimens.

Key Takeaways

• Openwater's open-source LIFU device deployed at NC State, UNC
• Study targets transverse myelitis, essential tremor, spinal cord injury
• Portable, noninvasive ultrasound offers alternative to DBS and drugs
• Open-LIFU already used at MIT and Barcelona research institute
• Open-source hardware enables custom neuromodulation research worldwide

Pulse Analysis

Low‑intensity focused ultrasound (LIFU) is emerging as a versatile neuromodulation tool, and Openwater’s decision to release an open‑source, portable version marks a turning point for academic research. By eliminating proprietary barriers, the Open‑LIFU platform lets engineers and clinicians rapidly prototype stimulation protocols, integrate real‑time feedback, and share code across institutions. This democratization mirrors trends in other medical technologies, where open hardware accelerates validation and drives cost reductions, making advanced therapies accessible beyond elite research centers.

The Sharma Lab’s multi‑site program targets three high‑impact use cases: transverse myelitis, essential tremor, and spinal‑cord injury rehabilitation. In transverse myelitis, focused ultrasound aims to attenuate inflammation‑driven spasticity without the systemic side effects of steroids. For essential tremor, researchers will compare transient modulation of tremor pathways against the gold‑standard deep‑brain stimulation, potentially offering a repeatable, outpatient solution. The spinal‑cord injury cohort will explore whether targeted ultrasound can restore motor circuitry, a question that could redefine post‑injury therapy. Early data from MIT and the University of Arizona suggest measurable changes in neural excitability, bolstering confidence in these clinical trials.

Beyond the immediate studies, Open‑LIFU’s open‑source architecture could catalyze a broader shift in neuro‑technology commercialization. Companies may adopt the platform as a development sandbox, shortening time‑to‑market for novel neuromodulation indications while reducing R&D spend. Regulators are also watching the trend, as standardized, transparent hardware eases safety assessments. If the Sharma Lab’s trials confirm efficacy, the market could see a surge in non‑invasive, software‑driven therapies, challenging the dominance of implantable devices and opening new revenue streams for both startups and established med‑tech firms.